Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | F7 | P08709 | 3/20 | 0.55 |
| ▸ | F3 | P13726 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | FABP3 | P05413 | 2/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44603 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL2722281 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL17743830 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL17744103 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL21197440 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL21197439 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL12186743 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL6037208 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL20603893 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 | |
| SCHEMBL2640803 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4ALDH1A1KDM4EF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050378-A1 | LIPID NANOPARTICLE COMPOSITIONS CONTAINING MONOESTER CATIONIC LIPIDS | MERCK SHARP & DOHME LLC (US) | 2024-02-15 | — | — | US | disclosed |
| EP-4255888-A2 | LIPID NANOPARTICLE COMPOSITIONS CONTAINING MONOESTER CATIONIC LIPIDS | Merck Sharp & Dohme LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022119883-A2 | LIPID NANOPARTICLE COMPOSITIONS CONTAINING MONOESTER CATIONIC LIPIDS | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20180208545-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9981907-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170022146-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022146-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-9458090-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458090-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150284317-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2015-10-08 | — | — | US | disclosed |
| US-20150284317-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2015-10-08 | — | — | US | disclosed |
| US-9029590-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029590-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130274504-A1 | Novel Low Molecular Weight Cationic Lipids For Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-10-17 | — | — | US | disclosed |
| US-20130274504-A1 | Novel Low Molecular Weight Cationic Lipids For Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208545-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | FFAR1 579/4885FFAR4 741/4885ALDH1A1 4239/4885 |
| US-20130274504-A1 | Novel Low Molecular Weight Cationic Lipids For Oligonucleotide Delivery | LDLR, APOB, CETP | FFAR1 579/4885FFAR4 741/4885ALDH1A1 4239/4885 |
| US-20150284317-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | FFAR1 579/4885FFAR4 741/4885ALDH1A1 4239/4885 |
| US-20170022146-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | FFAR1 579/4885FFAR4 741/4885ALDH1A1 4239/4885 |
| US-20240050378-A1 | LIPID NANOPARTICLE COMPOSITIONS CONTAINING MONOESTER CATIONIC LIPIDS | LIPA, LIPC, MGLL | FFAR1 380/4885FFAR4 375/4885ALDH1A1 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.